undamentalytics Newsletter
Sign in

Cytokinetics Inc income statement

In fiscal 2025, Cytokinetics Inc reported revenue of $88.0m, up 376.6% on the year before, operating income of −$612m (a -695.4% margin) and net income of −$785m, or −$6.54 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue823483147291061332275670958188868
Research and development403837364944466090898697160241330339416397
General and administrative16141412151720283631405397178174215284—
Operating income26−50−48−40−34−15−3719−113−89−99−94−186−324−496−536−612−708
Interest expense—0000003347161619283846—
Income before tax25−49−48−40−34−15−3816−128−106————————
Income tax0−0000000000000000—
Net income25−49−48−40−34−15−3816−128−106−122−127−215−389−526−590−785−894
Diluted EPS$2.52−$4.62−$4.32−$2.30−$1.24−$0.41−$0.97$0.39−$2.59−$1.95−$2.11−$1.97−$2.80−$4.33−$5.45−$5.26−$6.54−$7.18
Diluted shares (average)10m11m12m18m27m36m39m43m49m54m58m65m77m90m97m112m120m124m
EBITDA28−48−47−40−33−14−3719−111−88−98−92−184−318−484−527−602−695

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CYTK vs RXRXABCL vs CYTKCYTK vs WVECUVL vs CYTK

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Cytokinetics Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Cytokinetics Inc.